Trial · NCT04513665
ZW25 in Women With Endometrial Cancers
NCT04513665, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2024-10-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ZW25 in Women With Endometrial Cancers. Trials, record NCT04513665. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04513665
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ZW25 in Women With Endometrial Cancers
- NCT number
- NCT04513665
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Endometrial Cancer, Carcinosarcoma
- Interventions
- ZW25
- First posted
- 2020-08-14
- Last updated
- 2025-05-22
- Results first posted
- 2024-10-21
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate/ORR of Participants | </= 24 weeks from the start of treatment | ORR = Compete Response (CR) + Partial Response (PR) by RECIST v 1.1 \</= 24 weeks from the start of treatment |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate/ORR of Participants | </= 24 weeks from the start of treatment | No participants accrued to Stage 2 arm | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate/ORR of Participants | Stage 1 | Participants with ORR (CR + PR) | 1 | Participants | |
| Overall Response Rate/ORR of Participants | Stage 1 | Participants without ORR (CR + PR) | 15 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Stage 1 | 16 | |
| Overall Study | STARTED | Stage 2 | 0 | |
| Overall Study | COMPLETED | Stage 1 | 0 | |
| Overall Study | COMPLETED | Stage 2 | 0 | |
| Overall Study | NOT COMPLETED | Stage 1 | 16 | |
| Overall Study | NOT COMPLETED | Stage 2 | 0 |
Source ClinicalTrials.gov
Adverse events130
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Stage 1 | 1 | 16 | |
| other | Abdominal distension | Gastrointestinal disorders | Stage 2 | 0 | ||
| other | Abdominal pain | Gastrointestinal disorders | Stage 1 | 2 | 16 | |
| other | Abdominal pain | Gastrointestinal disorders | Stage 2 | 0 | ||
| other | Allergic reaction | Immune system disorders | Stage 1 | 1 | 16 | |
| other | Allergic reaction | Immune system disorders | Stage 2 | 0 | ||
| other | Alopecia | Skin and subcutaneous tissue disorders | Stage 1 | 1 | 16 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Stage 2 | 0 | ||
| other | Anemia | Blood and lymphatic system disorders | Stage 1 | 1 | 16 | |
| other | Anemia | Blood and lymphatic system disorders | Stage 2 | 0 |
1 to 10 of 130Source ClinicalTrials.gov
See all 130 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Stage 1 | 8 | 16 |
| Total, all-cause mortality | Stage 2 | 0 | 0 |
| Total, other adverse events | Stage 1 | 16 | 16 |
| Total, other adverse events | Stage 2 | 0 | 0 |
| Total, serious adverse events | Stage 1 | 2 | 16 |
| Total, serious adverse events | Stage 2 | 0 | 0 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38262242 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04513665
GET https://conductscience.org/api/trials/v1/NCT04513665/events?page=2